<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Bladder Carcinoma - Okell Surgery Notes</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams'
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="06-benign-prostatic-enlargement.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 11.6%;"></div>
                        </div>
                       <span class="progress-text">Topic 7 of 60</span>
                    </div>
                    <a href="08-breast-cancer.html" class="nav-button">
                        <span class="nav-text">Next: Breast Cancer</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">BLADDER CARCINOMA</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <!-- START: introduction -->
                <section id="introduction" class="content-section">
                    <div class="content-card">
                        <h3>Introduction</h3>
                        <ul class="enhanced-list">
                            <li>Bladder cancer is a common urologic cancer.</li>
                            <li>4th most common tumour in men after lung, prostate and colorectal cancer.</li>
                            <li>Most cases are transitional cell carcinoma (TCC) worldwide, often described as polyclonal field change defects. In Kenya the TCC and SCC are thought to be about 50% each.</li>
                            <li>Urothelium in the entire urinary tract may be involved, including the renal pelvis, ureter, bladder, and urethra.</li>
                        </ul>
                        <p><strong>Nonurothelial primary bladder tumors</strong> are rare and may include:</p>
                        <ol>
                            <li>Primary lymphoma</li>
                            <li>Rhabdomyosarcoma</li>
                            <li>Small cell carcinoma</li>
                            <li>Carcinosarcoma</li>
                            <li>Sarcoma</li>
                        </ol>

                        <h4>Demographics</h4>
                        <ul class="enhanced-list">
                            <li><strong>Sex:</strong> The male-to-female ratio is 3:1. Women generally have a worse prognosis than men.</li>
                            <li><strong>Age:</strong> The median age at diagnosis is 68 years, and the incidence increases directly with age</li>
                            <li><strong>Race:</strong> Bladder cancer is more common in whites than blacks; however, blacks have a worse prognosis</li>
                        </ul>
                    </div>
                </section>
                <!-- END: introduction -->

                <!-- START: pathophysiology-etiology -->
                <section id="pathophysiology-etiology" class="content-section">
                    <h2 class="section-heading">Pathophysiology & Etiology</h2>
                    <div class="content-card">
                        <h3>Pathophysiology</h3>
                        <ul class="enhanced-list">
                            <li><strong>Adenocarcinomas:</strong> Account for less than 2% of primary bladder tumors. Observed most commonly in exstrophic bladders and persistent urachus. Poorly responsive to radiation and chemotherapy. Radical cystectomy is the treatment of choice.</li>
                            <li><strong>Squamous cell carcinomas (SCC):</strong> Most are associated with persistent inflammations from chronic cystitis-schistosomiasis, long-term indwelling Foley catheters, or bladder stones.</li>
                            <li><strong>Small cell carcinomas:</strong> Arise from neuroendocrine stem cells; aggressive tumors with poor prognosis.</li>
                            <li><strong>Carcinosarcomas:</strong> Highly malignant tumors containing both mesenchymal and epithelial elements.</li>
                            <li><strong>Leiomyosarcoma:</strong> Most common sarcoma of the bladder.</li>
                            <li><strong>Rhabdomyosarcomas:</strong> Most commonly occur in children; poor prognosis.</li>
                        </ul>

                        <h3>Predisposing Factors</h3>
                        <h4>Environmental</h4>
                        <ol class="enhanced-list">
                            <li><strong>Cigarette Smoking:</strong> Nitrosamine, 2-naphthylamine, and 4-aminobiphenyl are possible carcinogenic agents.</li>
                            <li><strong>Industrial exposure:</strong> Aromatic amines in dyes, paints, solvents, leather dust, inks, combustion products, rubber, and textiles.</li>
                            <li><strong>Prior radiation treatments:</strong> To the pelvis.</li>
                            <li><strong>Cyclophosphamide:</strong> Exposure to acrolein (urinary metabolite) increases risk.</li>
                            <li><strong>Artificial sweeteners:</strong> (eg, saccharin, cyclamate).</li>
                        </ol>

                        <h4>Squamous Cell Carcinoma (SCC) Risk Factors</h4>
                        <ul class="enhanced-list">
                            <li>Chronic cystitis (Schistosomiasis)</li>
                            <li>Long-term indwelling Foley catheters</li>
                            <li>Bladder stone</li>
                        </ul>

                        <h4>Genetic</h4>
                        <ul class="enhanced-list">
                            <li>Mutations of tumor suppressor gene p53 (chromosome 17) and Rb gene (chromosome 13).</li>
                            <li>Mutations of tumor suppressor genes p15 and p16 (chromosome 9).</li>
                        </ul>
                    </div>
                </section>
                <!-- END: pathophysiology-etiology -->

                <!-- START: clinical-presentation -->
                <section id="clinical-presentation" class="content-section">
                    <h2 class="section-heading">Clinical Presentation</h2>
                    <div class="content-card">
                        <h3>History</h3>
                        <ol class="enhanced-list">
                            <li><strong>Painless global hematuria:</strong> mostly gross hematuria but may be microscopic.</li>
                            <li><strong>Irritative symptoms:</strong> dysuria, frequency, urgency.</li>
                            <li><strong>Obstructive symptoms:</strong> especially around the bladder neck (poor stream, straining, incomplete emptying).</li>
                            <li>Passage of tissue particles.</li>
                            <li><strong>Mucosuria:</strong> Suggestive of Adenocarcinoma.</li>
                            <li><strong>Renal failure signs:</strong> edema.</li>
                            <li><strong>Advanced disease:</strong> Back pains, Hematochizia, Pain on defecation, Bone pain/weight loss.</li>
                        </ol>

                        <h3>Physical examination</h3>
                        <p>Clinical examination is usually normal, although an abdominal or pelvic mass may be palpable in those with advanced disease.<br>
                        Anemia - due to hematuria.</p>

                        <h3>Differential Diagnosis (Causes of hematuria)</h3>
                        <ul class="enhanced-list">
                            <li>Hemorrhagic Cystitis: Noninfectious</li>
                            <li>Nephrolithiasis</li>
                            <li>Renal Cell Carcinoma</li>
                            <li>Transitional Cell Carcinoma, Renal</li>
                            <li>Ureteral Trauma</li>
                            <li>UTI</li>
                        </ul>
                    </div>
                </section>
                <!-- END: clinical-presentation -->

                <!-- START: investigations -->
                <section id="investigations" class="content-section">
                    <h2 class="section-heading">Investigations</h2>
                    <div class="content-card">
                        <h3>Laboratory</h3>
                        <ol class="enhanced-list">
                            <li><strong>FHG:</strong> Hb (Anaemia), WBC (UTI), Platelets (Hemorrhage).</li>
                            <li><strong>Urinalysis:</strong> Nitrites (UTI). Microscopy: In surgical hematuria RBCs are not dysmorphic; in medical causes RBCs may appear dysmorphic.</li>
                            <li><strong>Urine cytology:</strong> For malignant cells.</li>
                            <li><strong>U/E/C:</strong> Upper tract involvement.</li>
                            <li><strong>Tumour markers:</strong> Bladder tumor antigen [BTA-Stat], Nuclear matrix protein [NMP-22], Fibrin/fibrinogen degradation products [FDP], Telomerase.</li>
                            <li><strong>Flexible cystoscopy:</strong> Urine for cytology, Biopsy of lesions, Resection of superficial tumors.</li>
                        </ol>

                        <h3>Imaging</h3>
                        <ol class="enhanced-list">
                            <li><strong>IVU (Intravenous Pyelogram):</strong> Criterion standard for upper-tract urothelium imaging. Picks distortion caused by tumor.</li>
                            <li><strong>Retrograde pyelography</strong></li>
                            <li><strong>Pelvic ultrasonography:</strong> Cheap, available, no radiation. Picks tumours in kidneys/bladder but poor in ureters.</li>
                            <li><strong>CT-scan:</strong> For staging.</li>
                            <li><strong>CXR:</strong> Rule out pulmonary metastasis.</li>
                        </ol>
                    </div>
                </section>
                <!-- END: investigations -->

                <!-- START: staging -->
                <section id="staging" class="content-section">
                    <h2 class="section-heading">TNM Staging for Bladder Cancer</h2>
                    <div class="content-card">
                        <div class="table-container">
                            <table>
                                <tr><td><strong>CIS</strong></td><td>Carcinoma in situ</td></tr>
                                <tr><td><strong>T0</strong></td><td>No tumour</td></tr>
                                <tr><td><strong>TX</strong></td><td>Tumour cant be assessed</td></tr>
                                <tr><td><strong>Ta</strong></td><td>Tumour confined to the epithelium</td></tr>
                                <tr><td><strong>T1</strong></td><td>Tumor invasion into the lamina propria</td></tr>
                                <tr><td><strong>T2</strong></td><td>Superficial muscle involvement</td></tr>
                                <tr><td><strong>T3a</strong></td><td>Deep muscle involvement</td></tr>
                                <tr><td><strong>T3b</strong></td><td>Perivesical fat involvement</td></tr>
                                <tr><td><strong>T4a</strong></td><td>Adjacent organs such as prostate, rectum</td></tr>
                                <tr><td><strong>T4b</strong></td><td>Pelvic sidewall involvement</td></tr>
                                <tr><td><strong>N+</strong></td><td>Lymph node metastasis</td></tr>
                                <tr><td><strong>M+</strong></td><td>Metastasis</td></tr>
                            </table>
                        </div>
                    </div>
                </section>
                <!-- END: staging -->

                <!-- START: management -->
                <section id="management" class="content-section">
                    <h2 class="section-heading">MANAGEMENT</h2>
                    <div class="content-card">
                        <h3>Medical Therapy</h3>
                        
                        <h4>Intravesical Immunotherapy (BCG)</h4>
                        <p><strong>Bacille Calmette-Guérin immunotherapy</strong></p>
                        <p><strong>Indication:</strong> CIS, T1 tumors, and high-risk Ta tumors. Decreases rate of recurrence and progression.</p>
                        <p><strong>Mechanism:</strong> Live attenuated strain of <em>Mycobacterium bovis</em>. Induces nonspecific, cytokine-mediated immune response.</p>
                        <aside class="callout warning">
                            <h4 class="callout-title">Contraindications & Side Effects</h4>
                            <p>Use of BCG is contraindicated in patients with <strong>gross hematuria</strong> (risk of systemic sepsis).<br>
                            Can cause granulomatous cystitis or prostatitis with bladder contraction. Can cause acute disseminated tuberculosis-like illness if enters bloodstream.</p>
                        </aside>

                        <h4>Intravesical Chemotherapy</h4>
                        <ul class="enhanced-list">
                            <li><strong>Valrubicin:</strong> For CIS refractory to BCG.</li>
                            <li>Others: Thiotepa, mitomycin C, doxorubicin, epirubicin.</li>
                        </ul>

                        <h4>Chemotherapy for Metastatic Cancer</h4>
                        <p>Standard treatment: MVAC (Methotrexate, Vinblastine, Adriamycin, Cisplatin).</p>

                        <h3>Surgical Care</h3>

                        <h4>A) Superficial bladder cancer (Ta, T1, CIS)</h4>
                        <p>Endoscopic resection and fulguration. Continued surveillance is mandatory.</p>

                        <h4>B) Organ-confined, muscle-invasive bladder cancer (T2, T3)</h4>
                        <p><strong>Radical cystectomy with urinary diversions:</strong></p>
                        <ul class="enhanced-list">
                            <li><strong>Men:</strong> Removal of bladder, prostate, and pelvic lymph nodes.</li>
                            <li><strong>Women:</strong> Anterior pelvic exenteration (bladder, urethra, uterus, ovaries, anterior vaginal wall).</li>
                        </ul>

                        <h5>Urinary Diversions:</h5>
                        <ul>
                            <li><strong>Ileal conduit (Incontinent):</strong> Segment of ileum used to conduct urine to stoma. Urine continuously collects in bag.</li>
                            <li><strong>Indiana pouch (Continent):</strong> Reservoir created from right colon and terminal ileum. Continence mechanism is ileocecal valve. Empty via clean intermittent catheterization.</li>
                        </ul>

                        <h4>C) Locally advanced tumour (T4)</h4>
                        <p>Treatment with radical radiotherapy. Role of salvage cystectomy if recurrence with radiotherapy.</p>
                    </div>
                </section>
                <!-- END: management -->

            </main>

            <!-- Bottom Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="06-benign-prostatic-enlargement.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 11.6%;"></div>
                        </div>
                       <span class="progress-text">Topic 7 of 60</span>
                    </div>
                    <a href="08-breast-cancer.html" class="nav-button">
                        <span class="nav-text">Next: Breast Cancer</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>
        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>